LCA5L Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-24951
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry/ Immunofluorescence
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This antibody has been engineered to specifically recognize the recombinant protein LCA5L using the following amino acid sequence: FVKEEQELPPKIIEVIHPERESNQEDVLVREKFKRSMQRNGVDDTLGKGTAPYTKGPLRQRRHYSFTEATENLHHGLPA
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for LCA5L Antibody
Immunocytochemistry/Immunofluorescence: LCA5L Antibody [NBP3-24951]
Staining of human cell line SiHa shows localization to nucleoplasm & plasma membrane.Applications for LCA5L Antibody
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
0.25-2 µg/ml
Application Notes
For ICC/IF, we recommend using a combination of PFA and Triton X-100. This will give you the optimal results for your experiments.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, pH 7.2, 40% glycerol
Preservative
0.02% Sodium Azide
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: LCA5L
Alternate Names
C21orf13, Leber congenital amaurosis 5-like, leber congenital amaurosis 5-like protein, Lebercilin-like protein, MGC33295
Gene Symbol
LCA5L
Additional LCA5L Products
Product Documents for LCA5L Antibody
Product Specific Notices for LCA5L Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...